comprehensive -WSS

comprehensive

author：focus 2025-10-01 22:49:22 - browse：11

A sign of Elevance Health behind some flowers — coverage from STAT — Michael Conroy/AP

These days, the surefire way to get ahead in health insurance is to become a health care provider, and Elevance just upped the ante. It’s joining with private equity to launch a $4 billion primary care company.

Elevance leaders divulged more about the company’s venture with Clayton, Dubilier & Rice on its first quarter earnings call Thursday. The partners announced the new company, yet unnamed, earlier this week, but the release was light on detail. The strategic partnership will house Elevance and CD&R’s doctors, clinics, and the technologies that help those doctors manage their patients.

Health insurers specialize in managing medical costs, and through ventures like this, they apply that expertise to managing patients’ chronic medical conditions. In arrangements like Medicare Advantage, where insurers are paid set amounts for members’ care, they’re incentivized to keep those patients healthy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： For Cytokinetics, FDA rejection of heart drug would help, not hinder

WSS

FDA's Pazdur wants cancer trials to range beyond China alone

Ultragenyx gene therapy for rare liver ailment succeeds in late

Change Healthcare can notify patients about the breach, HHS says

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

leisure time

Sports medicine is finally prioritizing gender equality

Woman returns to dialysis after doctors remove transplanted pig kidney

How one medical school became remarkably diverse

How to increase colonoscopy rates? Looks like an AI can help

How to save PrEP access — and even expand it

Anavex keeps shifting the goalposts in its clinical trials

The cancer drug shortage isn’t new — and neither are the solutions

Letters to First Opinion on caregivers, digital health, and more

The cancer drug shortage isn’t new — and neither are the solutions

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

focus

Emergent cuts jobs, executive role in business shake

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Methadone doses haven’t kept up in the age of fentanyl

Drastic changes should bring profitability, startup health insurers say

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

knowledge

hotspot

focus

leisure time